Oxford BioMedica plcOxford BioMedica plcOxford BioMedica plc

Oxford BioMedica plc

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪759.13 M‬GBP
‪−43.19 M‬GBP
‪128.80 M‬GBP
‪87.33 M‬
Beta (1Y)
1.50
Employees (FY)
861
Change (1Y)
+147 +20.59%
Revenue / Employee (1Y)
‪149.59 K‬GBP
Net income / Employee (1Y)
‪−50.16 K‬GBP

About Oxford BioMedica plc


CEO
Frank Mathias
Headquarters
Oxford
Founded
1996
ISIN
GB00BDFBVT43
FIGI
BBG000BMB7T9
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.

Check out other big names from the same industry as OXB.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
VMID
Vanguard FTSE 250 UCITS ETF
Weight
0.15%
Market value
‪4.43 M‬
USD
VMIG
Vanguard FTSE 250 UCITS ETF
Weight
0.15%
Market value
‪4.43 M‬
USD
MIDD
iShares FTSE 250 UCITS ETF
Weight
0.14%
Market value
‪1.32 M‬
USD
XASX
Xtrackers MSCI UK ESG UCITS ETF (DR) 1D- Distribution
Weight
0.05%
Market value
‪323.60 K‬
USD
GWX
SPDR S&P International Small Cap ETF
Weight
0.04%
Market value
‪321.02 K‬
USD
CSUKS.GBP
iShares MSCI UK Small Cap UCITS ETF
Weight
0.17%
Market value
‪227.13 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of OXB is 630 GBX — it has decreased by −1.41% in the past 24 hours. Watch Oxford BioMedica plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Oxford BioMedica plc stocks are traded under the ticker OXB.
OXB stock has risen by 8.25% compared to the previous week, the month change is a −1.72% fall, over the last year Oxford BioMedica plc has showed a 47.89% increase.
We've gathered analysts' opinions on Oxford BioMedica plc future price: according to them, OXB price has a max estimate of 970.00 GBX and a min estimate of 451.00 GBX. Watch OXB chart and read a more detailed Oxford BioMedica plc stock forecast: see what analysts think of Oxford BioMedica plc and suggest that you do with its stocks.
OXB reached its all-time high on Feb 25, 2000 with the price of 5,344 GBX, and its all-time low was 65 GBX and was reached on Jul 22, 2013. View more price dynamics on OXB chart.
See other stocks reaching their highest and lowest prices.
OXB stock is 3.02% volatile and has beta coefficient of 1.50. Track Oxford BioMedica plc stock price on the chart and check out the list of the most volatile stocks — is Oxford BioMedica plc there?
Today Oxford BioMedica plc has the market capitalization of ‪759.13 M‬, it has increased by 7.94% over the last week.
Yes, you can track Oxford BioMedica plc financials in yearly and quarterly reports right on TradingView.
Oxford BioMedica plc is going to release the next earnings report on Feb 25, 2026. Keep track of upcoming events with our Earnings Calendar.
OXB earnings for the last half-year are −0.25 GBX per share, whereas the estimation was −0.24 GBX, resulting in a −5.12% surprise. The estimated earnings for the next half-year are −0.08 GBX per share. See more details about Oxford BioMedica plc earnings.
Oxford BioMedica plc revenue for the last half-year amounts to ‪73.22 M‬ GBX, despite the estimated figure of ‪72.65 M‬ GBX. In the next half-year revenue is expected to reach ‪93.35 M‬ GBX.
OXB net income for the last half-year is ‪−26.36 M‬ GBP, while the previous report showed ‪−10.71 M‬ GBP of net income which accounts for −146.24% change. Track more Oxford BioMedica plc financial stats to get the full picture.
No, OXB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 29, 2025, the company has 861 employees. See our rating of the largest employees — is Oxford BioMedica plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Oxford BioMedica plc EBITDA is ‪−9.16 M‬ GBP, and current EBITDA margin is −18.08%. See more stats in Oxford BioMedica plc financial statements.
Like other stocks, OXB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oxford BioMedica plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oxford BioMedica plc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oxford BioMedica plc stock shows the buy signal. See more of Oxford BioMedica plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.